Prendiville C, O'Doherty M, Moriarty P, Cassidy L
RVEEH, Adelaide Road, Dublin, Ireland.
Br J Ophthalmol. 2008 Jun;92(6):823-5. doi: 10.1136/bjo.2006.111666. Epub 2008 Apr 11.
Experience with anti-tumour necrosis factor alpha medications in ophthalmology has been mainly in the treatment of resistant uveitis and scleritis. There have been a few case reports and one case series detailing the use of infliximab in the treatment of orbital inflammatory disease, but there is still limited experience with these agents in a variety of orbital inflammatory conditions. We describe successful suppression of inflammation with infliximab in the Idiopathic orbital inflammation, thyroid associated orbital inflammation and chronic relapsing inflammatory optic neuropathy.
This is a retrospective observational case series of five cases of orbital and ocular inflammation.
We describe effects of infliximab in the treatment of three cases of orbital inflammation and two cases of chronic relapsing inflammatory optic neuropathy, all of which were unresponsive to alternative immune modulators. The patients received relief of symptoms and signs of inflammation in all five cases. However, this relief was not absolute as symptoms returned around week 5 post-inflammation.
This report highlights the expanding role of the biological agents in ophthalmology. Although not the answer in treatment, they offer a valuable alternative to steroids in cases of refractory inflammation.
抗肿瘤坏死因子α药物在眼科的应用主要集中于治疗难治性葡萄膜炎和巩膜炎。已有一些病例报告及一个病例系列详细描述了英夫利昔单抗在眼眶炎性疾病治疗中的应用，但在各种眼眶炎性疾病中，这些药物的应用经验仍有限。我们描述了英夫利昔单抗在特发性眼眶炎症、甲状腺相关眼眶炎症及慢性复发性炎性视神经病变中成功抑制炎症的情况。
这是一项对5例眼眶及眼部炎症患者的回顾性观察病例系列研究。
我们描述了英夫利昔单抗对3例眼眶炎症及2例慢性复发性炎性视神经病变的治疗效果，所有这些病例对其他免疫调节剂均无反应。所有5例患者的炎症症状和体征均得到缓解。然而，这种缓解并非完全彻底，炎症症状在炎症后第5周左右又复发。
本报告强调了生物制剂在眼科领域不断扩大的作用。尽管它们并非治疗的万全之策，但在难治性炎症病例中，它们为类固醇药物提供了一种有价值的替代选择。
